Home / Textbooks / Others / pharmacy & drug therapy / Treatment of Cystic Fibrosis and Other Rare Lung Diseases 1st Edition 2017

Treatment of Cystic Fibrosis and Other Rare Lung Diseases 1st Edition 2017

Treatment of Cystic Fibrosis and Other Rare Lung Diseases 1st Edition 2017

Treatment of Cystic Fibrosis and Other Rare Lung Diseases 1st Edition 2017 (Milestones in Drug Therapy) 

This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions.

It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.

Editorial Reviews

Review

“The purpose is to focus on recent advances in understanding the molecular basis of these diseases, and how this understanding has helped develop novel targeted therapies. … The audience is clinicians, students, and researchers who want a deeper understanding of the pathogenesis and recent advances in the therapy of these rare diseases. … It should serve as a useful addition to the personal library of any interested pulmonologist or lung disease researcher.” (Santosh Dhungana, Doody’s Book Reviews, April, 2017)

Review

From the Back Cover

This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions.


It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.

Product details

  • File Size: 2519 KB
  • Print Length: 263 pages
  • Publisher: Springer; 1st ed. 2017 edition (January 28, 2017)
  • Publication Date: January 28, 2017
  • Sold by: Amazon Digital Services LLC
  • Language: English
  • ASIN: B01N4UIFYA

xfileloads

About med4u

Avatar

Check Also

Medical Education in Pulmonary, Critical Care and Sleep Medicine 1st Edition 2019

Medical Education in Pulmonary, Critical Care and Sleep Medicine: Advanced Concepts and Strategies (Respiratory Medicine)1st …

Leave a Reply

Skip to toolbar